In conclusion, our data support that the identified p53-CRISPR interactome (Figure 1) should be monitored for mutations in the clinical CRISPR/Cas9 setting, as cells with mutations in these genes, plausibly linked to cancer development, could be enriched by CRISPR/Cas9. Here, TP53 is linked to cancer.